Cardiovascular impact of switching to asciminib in chronic-phase chronic myeloid leukemia

Cliques: 33
ID: 323336
2026
PDF Gratuito
Metricas de Qualidade e Desempenho do Artigo
Qualidade Geral
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Avaliacao de Qualidade por IA
Nao analisado
Readership in this journal
Steady

Ranked #32 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Resumo
Abstract Background Among adenosine triphosphate-competitive tyrosine kinase inhibitors (ATP-TKIs) approved for chronic-phase chronic myeloid leukemia (CP-CML), nilotinib and ponatinib are associated with a high incidence of vascular adverse events, and cardiovascular monitoring is recommended in current cardio-oncology guidelines. In contrast, monitoring strategies for asciminib, a recently approved specifically targets the myristoyl pocket (STAMP) inhibitor, have not been addressed, and its real-world vascular impact remains unclear. Purpose To compare surrogate markers of atherosclerosis before and after switching from ATP-TKIs to asciminib in patients with CP-CML. Method This single-centre retrospective observational study included patients with CP-CML followed at a dedicated cardio-oncology clinic. Patients switched from ATP-TKIs to asciminib were identified. Arterial stiffness parameters, including cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI), were assessed before and after the switch. Cardiovascular events during follow-up were recorded. Results Among 102 patients in the cardio-oncology database, 45 were switched to asciminib. Thirty-two patients had complete arterial stiffness data before and after switching. Mean age at switching was 59.4 ± 12.8 years, and 65% were male. Approximately half had hypertension. No cardiovascular events requiring therapeutic intervention occurred during follow-up. ABI showed no significant change. In contrast, CAVI, a marker of arterial stiffness, showed a significant increase after asciminib initiation. Before switching, 21 patients had normal values (<8.0), 5 were borderline (8.0–8.9), and 6 were abnormal (≥9.0). Only one patient worsened from the normal to abnormal range. Conclusion Asciminib was not associated with clinically overt cardiovascular events in this cohort; however, a significant increase in arterial stiffness as assessed by CAVI was observed after treatment initiation. Given the age dependency of CAVI, causality cannot be confirmed. Larger studies are warranted to determine whether early increases in arterial stiffness are associated with future cardiovascular events and to clarify the need for vascular monitoring in these patients.
Chave de Referencia
openalex_W7172268211 Use esta chave para citacao automatica no manuscrito ao usar SciMatic Gerenciador de Manuscritos ou Gerenciador de Teses
Autores S Miyazaki, T Takaku, E Sato, N Watanabe, M Ando, T Minamino
Are you one of these authors? Claim your profile
Periodico European heart journal supplements : journal of the European Society of Cardiology
Ano 2026
DOI
10.1093/eurheartjsupp/suag097.117
URL
https://doi.org/10.1093/eurheartjsupp/suag097.117
Palavras-chave Palavras-chave nao encontradas

Citacoes

Nenhuma citacao encontrada. Para adicionar uma citacao, entre em contato com o administrador em info@scimatic.org

Comentarios

Nenhum comentario ainda. Seja o primeiro a comentar neste artigo.